FONT-SIZE Plus   Neg

Endocyte Inc. (ECYT) Is Up Sharply On Merck Agreement

Endocyte Inc. (ECYT: Quote) and Merck (MRK: Quote) announced Monday morning that they have entered into an agreement to develop and commercialize Endocyte's investigational therapeutic candidate, vintafolide. Merck, through a subsidiary, will gain worldwide rights to develop and commercialize vintafolide. Endocyte will receive a $120 million upfront payment and is eligible for milestone payments of up to $880 million.

Endocyte has gapped open sharply higher Monday and is now up 4.05 at $7.85 on above average volume. The stock has jumped to a 4-month high.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT